SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Rocon who wrote (18460)2/1/1999 8:24:00 PM
From: BigKNY3  Read Replies (1) of 23519
 
Rocon and Betty: <<Hopefully Charlie O's forthcoming report reiterating his strong buy will propel some upward price momentum this week.>>

The PaineWebber VVUS Analyst Report issued on 12/22/98 (VVUS@ 2.78)concluded as follows:

"Because Vivus recognizes just how vital a strong domestic marketing partnership is to its future vitality, we do not look for a final agreement to be reached by late January or February. Nonetheless, the delay in forging a new relationship has prompted us to reduce our 1999 EPS estimate by $0.10 to $0.50. Our rating on VVUS remains Buy for speculative,risk-oriented accounts".

BigKNY3

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext